We are live on ! Find out more

AMIX

Autonomix Medical

AMIX

Market cap $4.52M

4.65 USD

+0.07

1.53%

At close Updated Sep 9, 9:54 AM EDT

1 day

1.53%

5 days

0%

1 month

-49.95%

3 months

-45.29%

6 months

-48.96%

Year to date

-58.78%

1 year

-81.39%

5 years

-99.78%

10 years

-99.78%

About: Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.

Employees: 11

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Abstracts highlight potential of Autonomix's transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark.

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company's common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models.

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Recognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

Autonomix Medical Inc. (NASDAQ:AMIX) shares are skyrocketing Tuesday afternoon after securing U.S. Patent No. 12,433,670.

Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

Data demonstrate the ability to detect, localize and confirm changes in renal neural activity, supporting continued development of physiology-guided renal denervation

Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

Patent Broadens Intellectual Property Protecting Advanced Autonomic Nervous System Assessment Technologies Designed to Enhance Patient Selection, Treatment Precision and Future Clinical Applications THE WOODLANDS, TX, July 23, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods," further strengthening the Company's intellectual property portfolio supporting its proprietary autonomic nervous system technologies.

Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 12,611,134, titled “Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder.

Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

See News Rankings

Price charts implemented using Lightweight Charts™